-+ 0.00%
-+ 0.00%
-+ 0.00%

Abbisko's ABSK192 Shows Antitumor Activity in Preclinical Breast Cancer Studies

PUBT·11/19/2026 00:02:42
Listen to the news
Abbisko's ABSK192 Shows Antitumor Activity in Preclinical Breast Cancer Studies
  • Abbisko Medicine announced Nov. 19, 2026, that preclinical results for its subsidiary's CDK4 inhibitor ABSK192 were presented at the 2026 ENA symposium.
  • ABSK192 showed antitumor activity alone in HR-positive, HER2-negative breast cancer models; combinations with endocrine therapies or a PI3K inhibitor produced tumor regression.
  • The drug remains in development to support an investigational new drug application, with findings supporting further evaluation alone or in combinations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261119-12417989), on November 19, 2026, and is solely responsible for the information contained therein.